Impact of bacterial strain acquisition in the lung of patients with COPD: the AERIS study

Malvisi, Lucio; Yarraguntla, Aparna; Mortier, Marie-Cécile; Osman, Karen L.; Cleary, David W.; Sente, Béatrice; Pascal, Thierry; Weynants, Vincent; Clarke, Stuart C.; Taddei, Laura; Wilkinson, Tom; Devaster, Jeanne-Marie; Devos, Nathalie

doi:10.1080/23744235.2022.2092648

Cited by 2 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the correlation between pulmonary microorganisms and COPD deterioration, the follow-up research deeply explored the specific flora and its mechanism leading to the deterioration, and looked for the optimal consumption of potentially harmful bacteria in order to determine potential therapeutic interventions. 47 , 50 , 51 Analysis of the network of references reveals that the microbiome mainly studied in the top 10 cited references was from lung tissue and respiratory tract. The authors of these papers observed that the pulmonary microbiota would change when people with exacerbations of COPD, 31 , 32 and the increased microbiota members were mainly Proteus .…”

Section: Discussionmentioning

confidence: 99%

Global Research Trends on the Link Between the Microbiome and COPD: A Bibliometric Analysis

Chen¹,

Zeng²,

Liu³

et al. 2023

COPD

View full text Add to dashboard Cite

Background The pathogenesis of chronic obstructive pulmonary disease (COPD) has been studied in relation to the microbiome, providing space for more targeted interventions and new treatments. Numerous papers on the COPD microbiome have been reported in the last 10 years, yet few publications have used bibliometric methods to evaluate this area. Methods We searched the Web of Science Core Collection for all original research articles in the field of COPD microbiome from January 2011 to August 2022 and used CiteSpace for visual analysis. Results A total of 505 relevant publications were obtained, and the number of global publications in this field is steadily increasing every year, with China and the USA occupying the first two spots in international publications. Imperial College London and the University of Leicester produced the most publications. Brightling C from the UK was the most prolific writer, while Huang Y and Sze M from the USA were first and second among the authors cited. The American Journal of Respiratory and Critical Care Medicine had the highest frequency of citations. The top 10 institutions, cited authors and journals are mostly from the UK and the US. In the ranking of citations, the first article was a paper published by Sze M on changes in the lung tissue’s microbiota in COPD patients. The keywords “exacerbation”, “gut microbiota”, “lung microbiome”, “airway microbiome”, “bacterial colonization”, and “inflammation” were identified as cutting-edge research projects for 2011–2022. Conclusion Based on the visualization results, in the future, we can use the gut–lung axis as the starting point to explore the immunoinflammatory mechanism of COPD, and study how to predict the effects of different treatments of COPD by identifying the microbiota, and how to achieve the optimal enrichment of beneficial bacteria and the optimal consumption of harmful bacteria to improve COPD.

show abstract

Section: Discussionmentioning

confidence: 99%

Global Research Trends on the Link Between the Microbiome and COPD: A Bibliometric Analysis

Chen¹,

Zeng²,

Liu³

et al. 2023

COPD

View full text Add to dashboard Cite

show abstract

“…12 13 M. catarrhalis may also colonise the lower airways in stable COPD, which is associated to worsened COPD symptoms and increased risk of subsequent exacerbation. [14][15][16] M. catarrhalis is often found as a copathogen with other bacterial species or viruses 13 and thus, risk of lower respiratory tract infection with M. catarrhalis could be especially susceptible to changes in lung microbiome and immunosuppression.…”

Section: How This Study Might Affect Research Practice or Policymentioning

confidence: 99%

“…It is known to affect patients with COPD and is a common cause of bacterial exacerbation 12 13 . M. catarrhalis may also colonise the lower airways in stable COPD, which is associated to worsened COPD symptoms and increased risk of subsequent exacerbation 14–16…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inhaled corticosteroids and risk of lower respiratory tract infection withMoraxella catarrhalisin patients with chronic obstructive pulmonary disease

Johnsen,

Heerfordt,

Boel

et al. 2023

BMJ Open Resp Res

View full text Add to dashboard Cite

BackgroundUse of inhaled corticosteroids (ICS) is common in patients with chronic obstructive pulmonary disease (COPD) and has been associated with an increased risk of pneumonia.Moraxella catarrhalisis one of the most common bacterial causes of infectious exacerbation in COPD. Currently, to our knowledge, no studies have investigated if ICS increases the risk of lower respiratory tract infection withM. catarrhalisin patients with COPD.ObjectiveTo investigate if accumulated ICS use in patients with COPD, is associated with a dose-dependent risk of infection withM. catarrhalis.MethodsThis observational cohort study included 18 870 persons with COPD who were registered in The Danish Register of COPD. Linkage to several nationwide registries was performed.Exposure to ICS was determined by identifying all prescriptions for ICS, redeemed within 365 days prior to study entry. Main outcome was a lower respiratory tract sample positive forM. catarrhalis. For the main analysis, a Cox multivariate regression model was used.We defined clinical infection as admission to hospital and/or a redeemed prescription for a relevant antibiotic, within 7 days prior to 14 days after the sample was obtained.ResultsWe found an increased, dose-dependent, risk of a lower respiratory tract sample withM. catarrhalisamong patients who used ICS, compared with non-users. For low and moderate doses of ICS HR was 1.65 (95% CI 1.19 to 2.30, p=0.003) and 1.82 (95% CI 1.32 to 2.51, p=0.0002), respectively. In the group of patients with highest ICS exposure, the HR ofM. catarrhaliswas 2.80 (95% CI 2.06 to 3.82, p<0.0001). Results remained stable in sensitivity analyses. 87% of patients fulfilled the criteria for clinical infection, and results remained unchanged in this population.ConclusionOur study shows a dose-dependent increased risk of infection withM. catarrhalisassociated to ICS exposure.

show abstract

Impact of bacterial strain acquisition in the lung of patients with COPD: the AERIS study

Cited by 2 publications

References 35 publications

Global Research Trends on the Link Between the Microbiome and COPD: A Bibliometric Analysis

Global Research Trends on the Link Between the Microbiome and COPD: A Bibliometric Analysis

Inhaled corticosteroids and risk of lower respiratory tract infection withMoraxella catarrhalisin patients with chronic obstructive pulmonary disease

Contact Info

Product

Resources

About